antibody-drug conjugate | pharmaphorum

antibody-drug conjugate

News

Card image cap

Merck puts big bucks behind ADC alliance with China's Kelun

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech tha

News

Card image cap

SABCS: New ADC from AZ and Daiichi shows promise in breast c...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu is already making waves in breast cancer, and clinical results presented at the San Antonio Breast Cancer Symposium (S

Events

Partner Content

2nd Next-Generation Conjugates Summit

The 2nd Next-Generation Conjugates Summit, designed to help you push the boundaries of bioconjugate drug development with nex

Events

Partner Content

13th World ADC London 2023

With over 211 antibody-drug conjugate clinical trials breaking ground so far throughout 2022, a plethora of positive clinical results, expansion of antibody-drug conjugates to novel indications, an

News

Card image cap

GSK's Blenrep hopes take a knock as drug fails trial

GSK has great expectations for its BCMA-directed cancer drug Blenrep, but a failed phase 3 trial in relapsed or refractory multiple myeloma has raised doubts about its prospects – and even

News

Card image cap

FDA sets Feb review date for Trodelvy in new breast cancer u...

Gilead Sciences will hear back from the FDA in February next year about its marketing application for Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer, billed b